VYCERITY

pharmaceutical preparations for human use for treatment of Huntington's Disease, chorea associated with Huntington's Disease, schizophrenia, adjunctive treatment of schizophrenia, cognitive impairment associated with schizophrenia, epilepsy, epileptic encephalopathy with continuous spike-and-wave during sleep, SCN8A-related epilepsy with encephalopathy, focal onset seizures, tardive dyskinesia, Parkinson's Disease, adjunctive treatment of Parkinson's Disease, Major Depressive Disorder, anhedonia in Major Depressive Disorder, inadequate response to treatment in Major Depressive Disorder, dyskinetic cerebral palsy, and neuro-immunological and neuro-endocrinological diseases, disorders, and conditions; pharmaceutical preparations for the diagnosis, prevention and treatment of psychiatric, neurological, hormonal, genetic and endocrine disorders and conditions; pharmaceutical preparations for human use for diagnosis, prevention and treatment of psychiatric, neurological, hormonal, genetic and endocrine diseases and disorders by gene therapy; pharmaceuticals for human use for the treatment of rare and orphan diseases, disorders and conditions of the neurological, hormonal, and endocrine systems; pharmaceutical preparations for the treatment of congenital adrenal hyperplasia